Positive top-line results have been reported from an exploratory phase 2a placebo-controlled clinical trial of cannabidiol (CBD, GW Pharmaceuticals) in patients with schizophrenia who had failed to respond adequately to first-line antipsychotic medications. DOES NOT CONTAIN THC.
Links
[1] http://www.ptcommunity.com/news/2015-09-16-000000/cannabinoid-shows-positive-results-treating-schizophrenia?utm_source=PTCommunity%20Headlines%202015-9-16&utm_campaign=PTNL2015-09-16&utm_medium=email
[2] http://rethinkpot.org/tags/schizophrenia
[3] http://rethinkpot.org/tags/gw-pharm
[4] http://rethinkpot.org/tags/cbd